Lyra Therapeutics (LYRA) Operating Income (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Operating Income of -$7.1 million in Q4 2025, down 14.13% on a QoQ basis from -$6.2 million in Q3 2025, and up 37.61% YoY from -$5.2 million in Q4 2024.
Lyra Therapeutics (LYRA) Operating Income (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Operating Income for 7 consecutive years, with -$7.1 million the latest figure, recorded in Q4 2025.
- Operating Income for Q4 2025 came in at -$7.1 million, up 37.61% year-over-year; the trailing twelve-month figure through Dec 2025 was -$31.0 million (up 67.8% YoY), and the FY2025 annual result was -$31.0 million, up 67.8% from the prior year.
- Operating Income for Q4 2025 stood at -$7.1 million, down from -$6.2 million in the prior quarter.
- The five-year high for Operating Income was -$6.2 million in Q3 2025, with the low at -$49.0 million in Q2 2024.
- A 5-year average of -$14.7 million and a median of -$13.0 million in 2021 frame the typical range for Operating Income.
- Across the five-year window, Operating Income sank 196.76% in 2024 and surged 81.98% in 2025, its largest moves.
- Lyra Therapeutics' Operating Income stood at -$13.6 million in 2021, then declined by 11.12% to -$15.2 million in 2022, then slipped by 8.72% to -$16.5 million in 2023, then jumped by 30.76% to -$11.4 million in 2024, then soared by 37.61% to -$7.1 million in 2025.
- The last three Operating Income figures came in at -$7.1 million (Q4 2025), -$6.2 million (Q3 2025), and -$8.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 133.12 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -7.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.12 Mn |
| Sep 30, 2025 | -6.24 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Dec 31, 2024 | -11.41 Mn |
| Sep 30, 2024 | -12.44 Mn |
| Jun 30, 2024 | -48.97 Mn |
| Mar 31, 2024 | -23.52 Mn |
| Dec 31, 2023 | -16.48 Mn |
| Sep 30, 2023 | -16.83 Mn |
| Jun 30, 2023 | -16.50 Mn |
| Mar 31, 2023 | -17.31 Mn |
| Dec 31, 2022 | -15.16 Mn |
| Sep 30, 2022 | -14.83 Mn |
| Jun 30, 2022 | -14.40 Mn |
| Mar 31, 2022 | -11.93 Mn |
| Dec 31, 2021 | -13.64 Mn |
| Sep 30, 2021 | -11.08 Mn |
| Jun 30, 2021 | -11.07 Mn |
| Mar 31, 2021 | -7.83 Mn |